Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin

Gynecologic Oncology

Volumn 102, Issue 1, 2006, Pages 98-102

  Lin, Amy ^a   Ryu, Janice ^a   Harvey, Danielle ^a   Sieracki, Barbara ^a   Scudder, Sidney ^a   Wun, Ted ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Cervical carcinoma; Erythropoietin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; WARFARIN;

ADULT; AGE DETERMINATION; ARTICLE; BLOOD TRANSFUSION; BODY MASS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GYNECOLOGIC CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTHESIS; LEG THROMBOSIS; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOSIS; UTERINE CERVIX CANCER; VEIN THROMBOSIS; VULVOVAGINAL DISEASE;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOSIS; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS; WARFARIN;

EID: 33744935260     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.031     Document Type: Article

References (34)

1. Levine M.N., Lee A.Y., and Kakkar A.K. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J. Thromb. Haemost. 1 (2003) 1456-1463
2. Lee A.Y., and Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 107 (2003) I17-I21
3. Lee A.Y., and Levine M.N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin. Thromb. Hemost. 25 (1999) 137-145
4. Ross A.H., Griffith C.D., Anderson J.R., and Grieve D.C. Thromboembolic complications with silicone elastomer subclavian catheters. JPEN J. Parenter. Enteral Nutr. 6 (1982) 61-63
5. Baglin T.P., and Boughton B.J. Central venous thrombosis due to bolus injections of antileukaemic chemotherapy. Br. J. Haematol. 63 (1986) 606-607
6. Eastridge B.J., and Lefor A.T. Complications of indwelling venous access devices in cancer patients. J. Clin. Oncol. 13 (1995) 233-238
7. Harrison L., Shasha D., Shiaova L., et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin. Oncol. 28 (2001) 54-59
8. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91 (1999) 1616-1634
9. Barrett-Lee P.J., Bailey N.P., O'Brien M.E., and Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br. J. Cancer 82 (2000) 93-97
10. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100 (2002) 2303-2320
11. Demetri G.D., Kris M., Wade J., Degos L., and Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16 (1998) 3412-3425
12. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19 (2001) 2865-2874
13. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
14. Littlewood T.J. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin. Oncol. 28 (2001) 49-53
15. Albain K.S., Crowley J.J., LeBlanc M., and Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol. 9 (1991) 1618-1626
16. Wun T., Law L., Harvey D., et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 (2003) 1514-1520
17. Couban S., Goodyear M., Burnell M., et al. A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood 100 (2002) 703A
18. Heaton D.C., Han D.Y., and Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern. Med. J. 32 (2002) 84-88
19. Bern M.M., Lokich J.J., Wallach S.R., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann. Intern. Med. 112 (1990) 423-428
20. Boraks P., Seale J., Price J., et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br. J. Haematol. 101 (1998) 483-486
21. Hirsh J., Dalen J., and Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 119 (2001) 1S-2S
22. Mattos M.A., Londrey G.L., Leutz D.W., et al. Color-flow duplex scanning for the surveillance and diagnosis of acute deep venous thrombosis. J. Vasc. Surg. 15 (1992) 366-375
23. Rose S.C., Zwiebel W.J., Nelson B.D., et al. Symptomatic lower extremity deep venous thrombosis: accuracy, limitations, and role of color duplex flow imaging in diagnosis. Radiology 175 (1990) 639-644
24. Lavey R.S., Liu Y.S., Greer B.E., et al. Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group Study. [abstract]. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) S190-S191
25. Jacobson G.M., Kamath R.S., Smith B.J., and Goodheart M.J. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol. Oncol. 96 (2005) 470-474
26. Bowers P., Update on the safety of erythropoietin products in patients with cancer. 2004;CS-19. Ref Type: Slide.
27. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4 (2003) 459-460
28. Bush R.S., Jenkin R.D., Allt W.E., et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer Suppl. 37 (1978) 302-306
29. Eifel P.J., Morris M., Wharton J.T., and Oswald M.J. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 29 (1994) 9-16
30. Perez C.A., Grigsby P.W., Nene S.M., et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer 69 (1992) 2796-2806
31. Tsang R.W., Fyles A.W., Kirkbride P., et al. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int. J. Radiat. Oncol. Biol. Phys. 32 (1995) 1319-1329
32. Fyles A.W., Milosevic M., Pintilie M., Syed A., and Hill R.P. Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother. Oncol. 57 (2000) 13-19
33. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
34. Goodnough L.T., Brecher M.E., Kanter M.H., and AuBuchon J.P. Transfusion medicine. First of two parts-blood transfusion. N. Engl. J. Med. 340 (1999) 438-447